Insider · CIK 0001995525
Olivier Loeillot
ceoofficerdirector
Files at RGEN (REPLIGEN CORP). First filing Nov 26, 2025, latest Oct 6, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 5
$0 bought, $6.2M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RGEN: REPLIGEN CORP
RGENOct 9, 2026 · close 173.88
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 20Weak | REPLIGEN CORP | $1.0M 5,535 shares | -12% | +84% from low-3% from high | |
| 20Weak | REPLIGEN CORP | $2.5M 12,946 shares | -23% | +85% from low0% from high | |
| 20Weak | REPLIGEN CORP | $977k 5,426 shares | -10% | +76% from low-1% from high | |
| 23Weak | REPLIGEN CORP | $504k 3,035 shares | -6% | - | |
| 50Moderate | REPLIGEN CORP | $1.2M 7,041 shares | -16% | +58% from low-1% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | RGEN REPLIGEN CORP | SOpen-market sale Common Stock10b5-1 | -1,333 | $178.75 | $238k | 45,788 | 6 d ago |
| Oct 5, 2026 | RGEN REPLIGEN CORP | MOption exercise Common Stock10b5-1 | +4,202 | $154.96 | $651k | 49,990 | 6 d ago |
| Oct 5, 2026 | RGEN REPLIGEN CORP | SOpen-market sale Common Stock10b5-1 | -4,202 | $190.00 | $798k | 45,788 | 6 d ago |
| Oct 5, 2026 | RGEN REPLIGEN CORP | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,202 | $0.00 | $0 | 8,405 | 6 d ago |
| Oct 2, 2026 | RGEN REPLIGEN CORP | FTax withholding Common Stock | -1,248 | $181.70 | $227k | 47,121 | 7 d ago |
| Sep 24, 2026 | RGEN REPLIGEN CORP | MOption exercise Common Stock10b5-1 | +8,404 | $154.96 | $1.3M | 56,773 | 17 d ago |
| Sep 24, 2026 | RGEN REPLIGEN CORP | SOpen-market sale Common Stock10b5-1 | -8,404 | $190.00 | $1.6M | 48,369 | 17 d ago |
| Sep 24, 2026 | RGEN REPLIGEN CORP | MOption exercise Common Stock10b5-1 | +4,542 | $155.38 | $706k | 52,911 | 17 d ago |
| Sep 24, 2026 | RGEN REPLIGEN CORP | SOpen-market sale Common Stock10b5-1 | -4,542 | $190.00 | $863k | 48,369 | 17 d ago |
| Sep 24, 2026 | RGEN REPLIGEN CORP | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,404 | $0.00 | $0 | 12,607 | 17 d ago |
| Sep 24, 2026 | RGEN REPLIGEN CORP | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,542 | $0.00 | $0 | 9,085 | 17 d ago |
| Sep 21, 2026 | RGEN REPLIGEN CORP | MOption exercise Common Stock10b5-1 | +5,426 | $141.79 | $769k | 53,795 | 20 d ago |
| Sep 21, 2026 | RGEN REPLIGEN CORP | SOpen-market sale Common Stock10b5-1 | -5,426 | $180.00 | $977k | 48,369 | 20 d ago |
| Sep 21, 2026 | RGEN REPLIGEN CORP | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,426 | $0.00 | $0 | 5,426 | 20 d ago |
| Sep 3, 2026 | RGEN REPLIGEN CORP | FTax withholding Common Stock10b5-1 | -2,842 | $169.61 | $482k | 51,404 | 34 d ago |
| Sep 4, 2026 | RGEN REPLIGEN CORP | SOpen-market sale Common Stock10b5-1 | -3,035 | $165.90 | $504k | 48,369 | 34 d ago |
| Nov 25, 2025 | RGEN REPLIGEN CORP | SOpen-market sale Common Stock10b5-1 | -7,041 | $170.00 | $1.2M | 35,898 | Nov 26, 2025 |
| Oct 2, 2025 | RGEN REPLIGEN CORP | FTax withholding Common Stock | -1,248 | $145.23 | $181k | 42,939 | Oct 6, 2025 |
| Sep 3, 2025 | RGEN REPLIGEN CORP | FTax withholding Common Stock | -2,506 | $116.18 | $291k | 44,187 | Sep 4, 2025 |
| Nov 20, 2024 | RGEN REPLIGEN CORP | FTax withholding Common Stock | -861 | $123.41 | $106k | 32,556 | Nov 21, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.